Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging
Sign Up to like & getrecommendations! Published in 2021 at "Neuroradiology"
DOI: 10.1007/s00234-021-02693-z
Abstract: We aimed to evaluate the utility of diffusion tensor imaging (DTI), dynamic contrast-enhanced (DCE), and dynamic susceptibility contrast (DSC) imaging for stratifying bevacizumab treatment outcomes in patients with recurrent high-grade glioma. Fifty-three patients with recurrent… read more here.
Keywords: bevacizumab treatment; contrast; high grade; grade glioma ... See more keywords
Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-81914-0
Abstract: A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value regarding response to neoadjuvant bevacizumab… read more here.
Keywords: microvessel density; bevacizumab; bevacizumab treatment; response ... See more keywords
Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma progressing after molecular targeted therapy: A multicenter prospective observational study
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000030871
Abstract: To evaluate the efficacy of atezolizumab plus bevacizumab treatment in patients with hepatocellular carcinoma (HCC) previously treated with molecular targeted agents (MTAs). Thirty-one patients treated with atezolizumab plus bevacizumab for unresectable HCC and previously treated… read more here.
Keywords: bevacizumab treatment; hepatocellular carcinoma; atezolizumab plus; treatment ... See more keywords
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-3407
Abstract: On May 29, 2020, the FDA approved atezolizumab for use in combination with bevacizumab, for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC) with no prior systemic treatment. The… read more here.
Keywords: atezolizumab bevacizumab; treatment; approval; bevacizumab treatment ... See more keywords
A prospective multicenter observational study of bevacizumab for the treatment of metastatic colorectal cancer in Chinese patients (Obtain study).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e15560
Abstract: e15560Background: Bevacizumab (BV) was approved in China seven years ago. Safety data from multicenter observational study was limited. To understand practical use of BV and confirm the correlation... read more here.
Keywords: study bevacizumab; observational study; bevacizumab treatment; study ... See more keywords
Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter]
Sign Up to like & getrecommendations! Published in 2022 at "Neuropsychiatric Disease and Treatment"
DOI: 10.2147/ndt.s392309
Abstract: of to of these tumors is challenging and involves not only surgical resection but also some adjuvant treatment. for the meningioma grade III treatment, pharmacotherapy be considered; however, it is still evidence level IV. 1… read more here.
Keywords: bevacizumab treatment; treatment high; high grade; evidence ... See more keywords
Case Report: Probable Cerebral Amyloid Angiopathy-Related Inflammation During Bevacizumab Treatment for Metastatic Cervical Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.669753
Abstract: Bevacizumab is an anti-angiogenic monoclonal antibody targeting Vascular Endothelial Growth Factor (VEGF) that induces the proliferation and migration of vascular endothelial cells thus, promoting vasculogenesis. Bevacizumab inhibits cancer angiogenesis, which is fundamental for either tumor… read more here.
Keywords: amyloid angiopathy; cerebral amyloid; bevacizumab; bevacizumab treatment ... See more keywords
How do serum lipid levels change and influence progression-free survival in epithelial ovarian cancer patients receiving bevacizumab treatment?
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1168996
Abstract: Background This study aimed to investigate how serum lipid levels affect epithelial ovarian cancer (EOC) patients receiving bevacizumab treatment and to develop a model for predicting the patients’ prognosis. Methods A total of 139 EOC… read more here.
Keywords: bevacizumab treatment; eoc patients; receiving bevacizumab; patients receiving ... See more keywords